The malaria parasite is highly dependent on a unique protein for infecting new mosquitoes. This protein could be a target for the development of new drugs. It was discovered recently by researchers from Radboud university medical center and colleagues from the Humboldt University of Berlin. The results were published in Cell Reports.Publication in Cell reports: link
Over a thousand people die from malaria every day. The disease is caused by a single-cell parasite (protozoan) that is transmitted by mosquitoes. Anti-malaria efforts currently focus on effective diagnostics, mosquito nets, insecticides and drugs. Additionally, a strong effort is being made at Radboud university medical center and other institutes to develop a vaccine. Effective policy has nearly halved the annual number of malaria deaths in the past ten years, but further decline has stagnated, partly because the malaria parasite is developing resistance to all known drugs.
Taco Kooij, theme Infectious diseases and global health discovered a protein in the mitochondrion of the malaria parasite that could be used as a target for such a new drug.
Powerhouses of the cellAlmost all cells in the body contain mitochondria: organelles that provide energy to power cellular processes. The single-cell malaria parasite also has a mitochondrion, which is vital to its survival. All mitochondria contain many different proteins, including ‘prohibitin’ proteins. But malaria researcher Kooij and his German colleagues have discovered that the mitochondrion in the parasite, besides the common prohibitins that can also be found in human cells, contains a unique prohibitin that can be found only in this protozoa and related microbes.
This protein appears to be crucial for the survival of the parasite. Kooij: "When we switched off the prohibitin in the parasite, we saw that it was no longer able to infect new mosquitoes. The prohibitin-free parasite was already struggling during the liver and blood stages of its life cycle, but the final blow was dealt when it tried to infect another mosquito: it failed to do so. Fertilization between male and female parasites in the mosquito midgut (see paragraph on the malaria cycle) did occur, but shortly afterwards, this new generation died without infecting the mosquito."
Voltage in the cellMany mitochondrial functions depend on the voltage differential across the mitochondrial membrane. This membrane potential results from a difference in concentration of positively and negatively charged molecules inside and outside the mitochondrion. "The unique parasite protein fulfills an important role in maintaining the potential. In future research we want to figure out the exact mechanism." A new drug could potentially be developed to disable the unique prohibitin protein. "The main advantage is that this protein is not present in humans, who therefore cannot be harmed if it is disabled”, Kooij explains.
Malaria cycleAfter a human has been bitten by an infected mosquito, the malaria parasite travels to the liver where it multiplies. Five to seven days later, the liver cells burst open and the parasite infects the red blood cells. Only then does the infected person start to show symptoms such as fever and flu-like symptoms, or worse. Some of the parasites circulating in the blood develop into sexually reproductive stages, which can infect other mosquitoes. Fertilization takes place in the mosquito’s midgut. Once infected, those mosquitoes transmit the parasite to another human during a subsequent blood meal. In this way the parasite spreads very efficiently through the population; one person infected with malaria could potentially infect over one hundred others.
Related news items
Terrestrial bacteria can grow on nutrients from space26 May 2020
Researchers from the Radboudumc describe in an article in Astrobiology that bacteria can survive on an 'extraterrestrial diet', which affected their pathogenic potential.read more
First clinical trial with genetically modified malaria vaccine completed22 May 2020
In an innovative study, Radboudumc and LUMC jointly tested a candidate vaccine based on a genetically weakened malaria parasite. The results of this clinical trial, published in Science Translational Medicine, show that the vaccine is safe and elicits a defense response against a malaria infection.read more
New step in the development of a vaccine against malaria22 May 2020
A new vaccine based on rodent malaria parasites achieved a 95% reduction in infection of the liver in humans. An international consortium publishes the results in Science Translational Medicine.read more
Retirement of RIMLS Laboratory Assistant Nelly Mulders-Langen19 May 2020
After more than 45 years, Nelly said goodbye to "her" Radboudumc. We are going to miss her dedication and collegiality, but we wish her al the best for the future in good health.read more